The Linux Of SARS-CoV-2 Vaccines Ready For Human Trials In Finland
Researchers at the universities of Eastern Finland and Helsinki have developed a so-called vector type vaccine that should be ready for human trials in about a month.
What "vector type" means is that the vaccine is delivered to the human body using a vector, which in this case is a harmless adenovirus. The adenovirus is engineered to make the cells of the mucous membranes in the nasal cavity to produce some of the surface proteins of the SARS-CoV-2 virus once it infects them. The body then produces antibodies against those proteins thus creating immunity against the SARS-CoV-2 virus.
The same vector (the adenovirus) has been used successfully many times before. The researchers believe it to be both safe and effective and as the method has been used before, the trials wouldn't have to be as extensive as normally in vaccine testing.
It has been dubbed the Linux of corona virus vaccines because it's completely IPR-free. No one can make any money off the invention. The production of vaccines was discontinued in Finland 15 years ago because it was deemed unfeasible to produce vaccines in a small country. The team has asked the Finnish government for help in funding the tests and the production of the vaccine.
Here's a press release covering the topic. It's translate by Google Translate and is in somewhat poor English.